PGI39 Budegt Impact Analysis of HCV Therapy Cost After Boceprevir Addition to Standard Therapeutic Regime
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.788
https://www.valueinhealthjournal.com/article/S1098-3015(12)02501-6/fulltext
Title :
PGI39 Budegt Impact Analysis of HCV Therapy Cost After Boceprevir Addition to Standard Therapeutic Regime
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02501-6&doi=10.1016/j.jval.2012.08.788
First page :
A333
Section Title :
Gastrointestinal Disorders
Open access? :
No
Section Order :
300